Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ultragenyx Pharmaceutical Inc. - Common Stock
(NQ:
RARE
)
29.02
-1.29 (-4.26%)
Streaming Delayed Price
Updated: 3:57 PM EDT, Sep 15, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ultragenyx Pharmaceutical Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status
September 09, 2025
FDA designates Ionis Breakthrough Therapy for Angelman syndrome after Phase 1/2 results showed functional improvements.
Via
Benzinga
Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
September 08, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Assessing Ultragenyx Pharmaceutical: Insights From 8 Financial Analysts
September 05, 2025
Via
Benzinga
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals
September 04, 2025
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.
Via
Benzinga
Earnings Scheduled For August 5, 2025
August 05, 2025
Via
Benzinga
What to Expect from Ultragenyx Pharmaceutical's Earnings
August 04, 2025
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
September 02, 2025
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
September 02, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Ultragenyx to Participate at Investor Conferences in September
August 29, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
August 29, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
August 25, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 21, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
August 21, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
August 18, 2025
Company expects to complete BLA submission in the fourth quarter of 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
August 17, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
August 13, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
August 09, 2025
From
Pomerantz LLP
Via
GlobeNewswire
8 Analysts Assess Ultragenyx Pharmaceutical: What You Need To Know
August 06, 2025
Via
Benzinga
Ultragenyx (RARE) Q2 Revenue Up 13%
August 06, 2025
Via
The Motley Fool
Topics
Intellectual Property
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Reports Mixed Q2 2025 Earnings, Beats Revenue Estimates and Narrows Loss
August 05, 2025
Ultragenyx Q2 2025 earnings show revenue beat and narrower loss, reaffirming full-year guidance. Shares rose slightly post-report amid mixed market sentiment.
Via
Chartmill
Topics
Earnings
Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update
August 05, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
August 05, 2025
From
Pomerantz LLP
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
August 04, 2025
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
August 01, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome
July 31, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update
July 30, 2025
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks
July 28, 2025
HC Wainwright initiates Ultragenyx at Buy with $80 target, citing strong rare disease pipeline and late-stage data expected by year-end.
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
July 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Beyond The Numbers: 7 Analysts Discuss Ultragenyx Pharmaceutical Stock
July 28, 2025
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
July 23, 2025
From
Pomerantz LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.